NextFin

Eli Lilly’s Tirzepatide Surpasses Keytruda to Become the World’s Top-Selling Drug in 2025

Summarized by NextFin AI
  • Eli Lilly's tirzepatide-based drugs, Mounjaro and Zepbound, generated $10.1 billion in Q3 2025, surpassing Merck's Keytruda, which earned $8.1 billion.
  • Eli Lilly's total revenue increased by 54% year-over-year to $17.6 billion, driven by a 62% growth in volume despite price reductions.
  • The rise of tirzepatide reflects a shift in the pharmaceutical industry, with metabolic disease treatments becoming the dominant revenue driver.
  • The GLP-1 market is projected to expand significantly, with obesity drug sales potentially reaching $150 billion by 2030.

NextFin news, on October 30, 2025, Eli Lilly and Company announced in its third-quarter earnings report that its tirzepatide-based drugs, Mounjaro (for type 2 diabetes) and Zepbound (for obesity and related indications), collectively generated $10.1 billion in sales during the quarter. This impressive performance has enabled Eli Lilly to surpass Merck’s cancer immunotherapy key drug Keytruda, which posted $8.1 billion in Q3 sales, thereby becoming the world’s top-selling pharmaceutical product for the first time.

The announcement was made in Indianapolis, USA, as part of Eli Lilly’s Q3 2025 financial results, which showed a total revenue increase of 54% year-over-year to $17.6 billion. Despite price reductions for the GLP-1 medicines — a strategic move amidst Republican President Donald Trump’s administration’s pressure on drug pricing — volume grew by 62%, underscoring the strong market demand.

Keytruda, Merck’s flagship anti-PD-1 immunotherapy that has dominated cancer care since its FDA approval in 2014, generated $8.1 billion in the same period, contributing to Merck’s total revenue of $17.3 billion. The fact that tirzepatide overtook Keytruda marks a pivotal moment in pharmaceutical sales hierarchy.

According to BioSpace, the combined sales of Mounjaro and Zepbound alone accounted for the vast majority of Lilly's key products sales, which totaled $11.98 billion in the quarter. This meteoric rise of tirzepatide-based drugs coincides with growing global prevalence of type 2 diabetes and obesity, particularly with Mounjaro’s recent approval for additional indications such as obstructive sleep apnea.

The drugs’ success is also supported by Eli Lilly's strategic direct-to-consumer (DTC) pricing initiatives. Through LillyDirect, insured patients can access Zepbound at a highly discounted $25 per pre-filled vial with savings cards, compared to an average retail price of $1,272 per month. This aggressive pricing tactic aims to broaden access and mitigate pricing pressures under the Trump administration’s pharma scrutiny.

Despite the impressive sales, Eli Lilly faces stiff competition from Novo Nordisk, which has pioneered GLP-1 analogs like semaglutide (branded as Ozempic and Wegovy). As of 2024, Novo led the obesity and diabetes segment with $26 billion global sales, but Lilly’s efficacy edge—especially in weight loss—has enabled rapid market share gains. Lilly also recently launched Mounjaro in India, tapping the world's largest populous market before Novo's similar entries.

Market analysts emphasize tirzepatide’s superior clinical profile. According to GlobalData analyst Costanza Alciati, Zepbound has demonstrated greater weight loss efficacy than Wegovy, with less associated muscle mass loss, and comparable safety profiles. These clinical advantages fuel Lilly’s accelerating sales trajectory, projecting it to remain the GLP-1 market leader into the foreseeable future.

The rise of tirzepatide and other GLP-1 receptor agonists reflects a profound pharmaceutical industry transformation: the metabolic disease treatment segment is becoming the dominant revenue driver, surpassing long-time blockbusters in oncology and immunology. This trend is corroborated by earlier blockbuster battles, such as Keytruda overtaking Opdivo in cancer, and Eliquis surpassing Xarelto in anticoagulation.

Looking forward, the GLP-1 market is expected to expand significantly, with some forecasts estimating the obesity drug market alone could reach $150 billion by 2030. Eli Lilly's recent clinical advances, including the development of an oral obesity medication, Orforglipron, position the company to capture an even larger share by addressing patient preferences for non-injectable therapies—a segment estimated to represent up to 25% of patients with needle aversion.

The competitive dynamic with Novo Nordisk continues to intensify. While Novo secured a significant formulary win with CVS Caremark making Wegovy preferred coverage starting July 2025, Lilly remains confident, emphasizing its 53% GLP-1 market share as of Q1 2025 and ongoing expansion of DTC platforms.

President Donald Trump’s administration’s emphasis on drug pricing reform creates both challenges and opportunities for manufacturers. Lilly’s aggressive price reduction strategies foster greater patient access but place pressure on margins. However, volume growth and market expansion appear sufficient to offset pricing concessions while maintaining robust revenue growth.

In conclusion, Eli Lilly’s tirzepatide franchise eclipsing Keytruda signifies a paradigm shift in the pharmaceutical industry’s revenue landscape, driven by the urgent global health crises of diabetes and obesity. This development under President Donald Trump’s current administration reflects evolving healthcare priorities and innovation focused on metabolic diseases. Moving forward, biopharma companies will increasingly invest in GLP-1s and related therapies, seeking to capitalize on burgeoning market demand, competitive pharmacy benefit manager dynamics, and the transition to oral and consumer-friendly administrations.

According to BioSpace, Eli Lilly will likely continue its growth trajectory supported by ongoing approvals, pipeline developments, and expanded access initiatives, solidifying its position as a global pharmaceutical powerhouse in the second half of the 2020s.

Explore more exclusive insights at nextfin.ai.

Insights

What are the key characteristics of tirzepatide as a drug?

How did Eli Lilly's sales strategy contribute to its success with tirzepatide?

What factors led to the rise of tirzepatide-based drugs in 2025?

How does tirzepatide compare to Merck's Keytruda in terms of sales and market impact?

What is the current market trend for GLP-1 receptor agonists?

What challenges does Eli Lilly face from competitors like Novo Nordisk?

How has the Trump administration's drug pricing policy affected pharmaceutical companies?

What recent developments have occurred in the GLP-1 drug market?

What implications does tirzepatide's success have for the future of diabetes and obesity treatments?

How do Eli Lilly's pricing strategies influence patient access to its drugs?

What is the projected growth of the obesity drug market by 2030?

How does the clinical efficacy of Zepbound compare with its competitors like Wegovy?

What role does direct-to-consumer marketing play in Eli Lilly's strategy?

How does the competitive landscape of diabetes treatments look as of 2025?

What historical shifts in the pharmaceutical industry are similar to Eli Lilly’s rise with tirzepatide?

What are the expected long-term effects of the shift towards GLP-1 medications on the pharmaceutical industry?

How do consumer preferences for non-injectable therapies impact drug development?

What are the potential risks associated with aggressive pricing strategies in the pharmaceutical industry?

How might Eli Lilly's drug pipeline influence its market position in the coming years?

What are the key differences between Mounjaro and other diabetes medications?

Search, ask or analyze anything...